Novel clinical strategies for the treatment of pancreatic carcinoma.
Pancreatic carcinoma ranks as the eighth most frequent type of solid tumour arising worldwide yet it represents the fourth most frequent cause of death. This discrepancy reflects the current lack of effective treatment available for the pancreatic cancer patient and highlights the urgent need for new therapeutic principles in this area. The last five years have seen an increasing number of novel approaches both in the pre-clinical area as well as in clinical trials for pancreatic cancer treatments. This review summarizes these new developments and attempts to rationalize the possibilities available for the patient at the beginning of the new millennium.
Günzburg
W H
WH
Institute of Virology, University of Veterinary Sciences, Veterinärplatz 1, A-1210 Vienna, Austria. walter.guenzburg@vu-wien.ac.at
Salmons
B
B
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001646:Bile; D001711:Biotransformation; D019496:Cancer Vaccines / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D002986:Clinical Trials as Topic; D019362:Cytochrome P-450 CYP2B1 / Q000008:administration & dosage / Q000235:genetics; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016373:DNA, Antisense / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004148:Dioxolanes / Q000627:therapeutic use; D010450:Endopeptidases / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016158:Genes, p53; D011905:Genes, ras; D015316:Genetic Therapy; D006360:Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D007069:Ifosfamide / Q000493:pharmacokinetics; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D014411:Neoplastic Stem Cells / Q000637:transplantation; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010368:Pectins / Q000627:therapeutic use; D010865:Pilot Projects; D011073:Polyamines / Q000627:therapeutic use; D011446:Prospective Studies; D019736:Prostheses and Implants; D012717:Sesquiterpenes / Q000627:therapeutic use; D013141:Spiro Compounds / Q000627:therapeutic use; D014020:Tissue Extracts; D059004:Topoisomerase I Inhibitors; D000093542:Gemcitabine
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016373:DNA, Antisense; D004148:Dioxolanes; D004791:Enzyme Inhibitors; C432804:GBC590; D006360:Heat-Shock Proteins; D009363:Neoplasm Proteins; D011073:Polyamines; D012717:Sesquiterpenes; D013141:Spiro Compounds; D014020:Tissue Extracts; D059004:Topoisomerase I Inhibitors; C079422:acylfulvene; C087098:virulizin; D003841:Deoxycytidine; C074908:troxacitabine; D010368:Pectins; D003596:Cytosine; D019362:Cytochrome P-450 CYP2B1; D010450:Endopeptidases; D007069:Ifosfamide; D000093542:Gemcitabine